SER
What one share of Serina Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications.
Serina Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.94 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.71 |
| Cash and investments | $0.91 |
| Book value | $0.74 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.05 | −$0.21 | $0.00 | −$0.21 | — | $0.22 |
| 2018 | $0.04 | −$0.21 | $0.00 | −$0.23 | — | $0.21 |
| 2019 | $0.05 | −$0.33 | $0.02 | −$0.29 | — | $0.06 |
| 2020 | $0.01 | −$0.29 | $0.00 | −$0.21 | — | −$0.14 |
| 2021 | $0.00 | −$0.23 | — | −$0.21 | — | −$0.31 |
| 2022 | $0.03 | −$9.70 | — | −$5.50 | — | −$35.01 |
| 2023 | $0.43 | $0.73 | $0.07 | −$0.41 | — | — |
| 2024 | $0.01 | −$1.51 | $0.00 | −$2.33 | — | $0.07 |
| 2025 | $0.01 | −$1.91 | $0.01 | −$1.77 | — | −$0.00 |